Table 2.

Characteristics of people with MS according to anti-PAD2 antibody status.

	Anti-PAD2+	Anti-PAD2–	p-Value
	(n = 17)	(n = 71)
Age (years), mean ±SD	50.8 ± 14.6	48.3 ± 12.0	0.47
Male, n (%)	4 (23.5%)	21 (29.6%)	0.78
White, n (%)	14 (82.4%)	51 (71.8%)	0.54
Duration of illness*(years), mean ±SD	16.6 ± 14.9	11.7 ± 9.1	0.10
Treatment*
Avonex, n (%)	2 (11.8%)	3 (4.2%)	0.25
Betaseron, n (%)	0 (0%)	1 (1.4%)	1.0
Rebif, n (%)	3 (17.6%)	7 (9.9%)	0.40
Copaxone, n (%)	6 (35.3%)	20 (28.2%)	0.57
Gilenya, n (%)	0 (0%)	1 (1.4%)	1.0
Lemtrada, n (%)	0 (0%)	1 (1.4%)	1.0
Tecfidera, n (%)	3 (17.6%)	6 (8.5%)	0.37
Rituximab, n (%)	0 (0%)	3 (4.2%)	1.0
Tysabri, n (%)	2 (11.8%)	12 (16.9%)	1.0

Anti-PAD2+, anti-PAD2 antibody positive; Anti-PAD2–, anti-PAD2 antibody negative.

*Duration of illness data was available for n = 87 and treatment data was available for n = 70 people.